Biophan Technologies Hires Jeffrey L. Helfer as Vice President of Engineering.

Business Editors/Health Writers

ROCHESTER, N.Y.--(BW HealthWire)--Oct. 23, 2001

Biophan Technologies, Inc. today announced it has hired Jeffrey L. Helfer as vice president of Engineering. In this position, Helfer will work closely with Wilson Greatbatch, inventor of the implantable pacemaker and its lithium battery, Stu MacDonald, Vice President of R&D, and Biophan manufacturing partners, as the company prepares to make a major announcement

Helfer joins Biophan with a solid background in product and technology development and systems management. Prior to Biophan, Helfer served in a number of positions at Ortho-Clinical Diagnostics in Rochester, New York, a division of Johnson & Johnson. Most recently, he was program director within OCD's Product Development and Program Management Center of Excellence. He was primarily responsible for systems management of the company's next-generation clinical chemistry platform and implementation of the Design for Six Sigma capabilities into the company's broader research and development organization.

"We are extremely pleased to have Jeff Helfer as the newest member of our management team," said Michael L. Weiner, chairman and CEO of Biophan. "He has extensive experience with product development, program management, and new business development. This experience will be vital as Biophan prepares to have a major impact on the medical community."

Prior to Ortho-Clinical Diagnostics, Helfer worked at Eastman Kodak Company for 19 years, most recently as the manager of the clinical diagnostics systems laboratory. He holds a B.S. from Rochester Institute of Technology and an M.S. from the University of Rochester, both in Mechanical Engineering. Helfer is a Johnson & Johnson certified Design for Six Sigma Black Belt and New York State Professional Engineer.

About Biophan

Biophan, based in Rochester and Buffalo, New York, is currently focusing on two technologies. The first is new proprietary technology that will enable implantable cardiac pacemakers and other life-sustaining medical devices to operate in the presence of magnetic resonance imaging (MRI) equipment. The underlying technology, which was acquired by the Company, is based on patent applications and proprietary knowledge developed by Wilson Greatbatch, the inventor of the original implantable cardiac pacemaker. The second technology is proprietary antisense gene therapy technology to inhibit the spread of human immunodeficiency virus (HIV-1) infection in conjunction with the use of lentiviral vectors. This technology is based on patents issued to Mr. Greatbatch and acquired by the Company.

Safe Harbor Statement:

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of the Company's MRI and gene therapy technologies; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.